Skip to content
Back Home
  • Home
  • About Us
    • Our History
    • Our Science
    • Our Partners
  • Scientific Platforms
    • ADCs
    • Publications
  • Team
  • News
  • Contact
Back Home
  • Search
  • Home
  • About Us
    • Our History
    • Our Science
    • Our Partners
  • Scientific Platforms
    • ADCs
    • Publications
  • Team
  • News
  • Contact
Home » Uncategorized » Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health
Uncategorized

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

by Mbio2018|Published September 1, 2018

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball=

Project Number: 1R43CA228746-01A1

Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

You may also like

Published August 12, 2022

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

https://www.accesswire.com/709117/Manhattan-BioSolutions-Inc-Signs-Commercial-Evaluation-License-Agreements-with-the-National-Institutes-of-Health-NIH-for-Use-of-Monoclonal-Antibodies-in-Novel-Antibody-Drug-Conjugate-ADC-Oncology-Programs NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation […]

Published April 8, 2025

Manhattan BioSolutions Secures Expanded Rights to Novel Legumain-Cleavable Topoisomerase 1 Inhibitor (TOP1i) ADC Platform After Successful Multi-Target Validation

Published May 12, 2020

Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers […]

Published September 9, 2020

Manhattan BioSolutions Announces Phase I SBIR Grant Award from the National Science Foundation

NEW YORK, NEW YORK, UNITED STATES, September 9, 2020 /EINPresswire.com/ — Manhattan BioSolutions, a biotechnology company focused on the discovery of the […]

Post navigation

  • Previous post Manhattan BioSolutions has won prestigious Johnson & Johnson Innovation QuickFire Challenge Competition and award to receive free laboratory and office space at the newly open JLabs@NYC incubator in downtown Manhattan
  • Back to post list
  • Next post Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

© 2025 Manhattan BioSolutions – All rights reserved

Powered by WP – Designed with the Customizr theme